LENZ Therapeutics Inc (LENZ) USD0.001
0.02%- This stock can be held in a
Stocks and Shares ISA
$1.72
(6.42%)$1.72
(6.42%)Company Information
About this company
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
Key people
Key facts
- EPICLENZ
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS52635N1037
- Market cap$754.60m
- Employees42
- Shares in issue28.15m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.